Drug Details
General Information of the Drug (ID: DR0366) | ||||
---|---|---|---|---|
Name |
Belinostat
|
|||
Synonyms |
Belinostat; 414864-00-9; PXD101; Belinostat (PXD101); 866323-14-0; Beleodaq; PXD-101; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; NSC726630; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; PXD 101; UNII-F4H96P17NZ; PX-105684; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; 2-Propenamide, N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-; F4H96P17NZ; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; CHEBI:61076; PX 105684; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide.; E-Belinostat; Belinostat [USAN:INN]; N-hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide; PX105684; 2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, (2E)-; Belinostat Ph3; Beleodaq (TN); PubChem22405; Belinostat - PXD101; Belinostat (USAN/INN); Belinostat (PXD101); N-Hydroxy-3-(3-phenylsulphamoylphenyl)acrylamide; cc-489; MLS006011091; CHEMBL408513; GTPL7496; BDBM25150; CHEBI:94531; AMY1792; DTXSID60194378; EX-A180; QCR-181; (E)-3-[3-(phenylsulfamoyl)phenyl]prop-2-enehydroxamic acid; BCPP000351; AOB87787; BCP01741; ZINC3818726; Belinostat,PXD101, PX105684; Belinostat/PXD101,PX105684/; ABP000140; MFCD08064035; NSC758774; s1085; AKOS025401741; BCP9000386; CCG-208758; DB05015; LS41098; NSC-726630; NSC-758774; SB16466; NCGC00263155-02; NCGC00263155-05; AC-25046; AS-17068; SMR004702879; AB0007889; SW219445-1; EC-000.2286; A25012; D08870; W-5363; J-523584; Q4882925; BRD-K17743125-001-01-9; N-Hydroxy-3-[(phenylamino)sulfonyl]-trans-cinnamamide; (E)-N-Hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide; 5OG
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 2 | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C15H14N2O4S
|
|||
PubChem CID | ||||
Canonical SMILES |
C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO
|
|||
InChI |
1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+
|
|||
InChIKey |
NCNRHFGMJRPRSK-MDZDMXLPSA-N
|
|||
CAS Number |
CAS 866323-14-0
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Vincristine | Catharanthus roseus | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SU-DHL-4 | CVCL_0539 | B-cell lymphoma | Homo sapiens | ||
DB | CVCL_1168 | B-cell lymphoma | Homo sapiens | |||
OCI-Ly19 | CVCL_1878 | B-cell lymphoma | Homo sapiens | |||
SU-DHL-8 | CVCL_2207 | B-cell lymphoma | Homo sapiens | |||
GM18564 | CVCL_P179 | Healthy | Homo sapiens | |||
Experimental
Result(s) |
Vincristine sensitizes DLBCL cells to the cytotoxic effects of belinostat. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Histone deacetylase (HDAC) | Molecule Info | [3] |

